Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
01/2003
01/02/2003US20030004355 Regulating intracellular levels of cyclic guanosine-3*,5*-monophosphate by activiating soluble guanylate cyclase or inhibiting phosphodiesterases
01/02/2003US20030004352 Contacting a racemic mixture of the piperidine carbinol in solution with ditoluoyltartaric acid, crystallising the salt and neutralizing
01/02/2003US20030004351 Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors
01/02/2003US20030004350 Pyrrolo(2,3-b)pyridine derivatives; anticancer and antiproliferative agents
01/02/2003US20030004344 Thrombin or factor Xa inhibitors
01/02/2003US20030004341 Antidiabetic agents and dietetics
01/02/2003US20030004340 Skin disorders; gastrointestinal disorders
01/02/2003US20030004321 Glycosylated analogs of fusidic acid
01/02/2003US20030004312 Antiseptics; acidity pH; destroying infections
01/02/2003US20030004310 Culture product
01/02/2003US20030004308 Anticoagulants
01/02/2003US20030004216 Mixture containing benzyllauryldimethylammonium bromide
01/02/2003US20030004215 Oral administering alpha-hydroxycarboxylic acid
01/02/2003US20030004214 Irritable bowel disease
01/02/2003US20030004213 Medicament against dysmenorrhoea and premenstrual syndrome
01/02/2003US20030004212 Cyclohexylamine derivatives as subtype selective N-Methyl-D-Aspartate antagonists
01/02/2003US20030004211 Carbohydrate modifying agent and drinks containing the modifying agent
01/02/2003US20030004210 Coupling to cell binding agent; killing cells
01/02/2003US20030004209 Anti-angiogenic compositions and methods of use
01/02/2003US20030004207 Use of compounds which activate a 5-ht receptor to treat urinary incontinence
01/02/2003US20030004206 Hypotensive agents; cardiovascular disorders
01/02/2003US20030004205 Carvedilol-hydrophilic solutions
01/02/2003US20030004204 Methods and compositions to treat lung diseases
01/02/2003US20030004203 Benzimidazole derivatives as modulators of IgE
01/02/2003US20030004201 Hypotensive agents; congestive heart failure; administering angiotensin receptors antagonist
01/02/2003US20030004200 Crystalline form of 4-[5-methyl-3-phenylisoxazol-4-YL] benzenesulfonamide
01/02/2003US20030004199 Administering endothelin antagonist
01/02/2003US20030004198 Stabilized isothiazolone-containing compositions
01/02/2003US20030004197 Composition with a continuous aqueous phase containing L-2-oxothiazoldine-4-carboxylic acid
01/02/2003US20030004196 Antiinflamamtory agents; autoimmune disease
01/02/2003US20030004195 Reducing pressure in eye
01/02/2003US20030004194 Method for treating fibrotic diseases or other indications VI
01/02/2003US20030004193 Immunomodulators; antiinflammatory agents
01/02/2003US20030004191 Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
01/02/2003US20030004187 Method for preventing dyskinesias
01/02/2003US20030004186 Anticoagulants; cardiovascular disorders; central nervous system disorders
01/02/2003US20030004182 Method for manufacturing a low dose pharmaceutical composition having uniform drug distribution and potency
01/02/2003US20030004180 Central nervous system disorders; psychological disorders
01/02/2003US20030004179 Treating allergic and inflammatory conditions
01/02/2003US20030004178 Synergistic mixture
01/02/2003US20030004177 Abuse-resistant opioid dosage form
01/02/2003US20030004176 Mixture of analgesic and addition reducting compound of a gamma-aminobutyric acid
01/02/2003US20030004175 Viricides
01/02/2003US20030004174 Antiinflammatory agents, anticancer agents, antihistamines, central nervous system disorders
01/02/2003US20030004173 Pharmaceutically active compounds
01/02/2003US20030004172 Cardiovascular disorders, osteoporosis, multiple sclerosis, antiarthritic agents
01/02/2003US20030004170 Mixture of adrenergic blocking agent and phosphodiesterase inhibitor
01/02/2003US20030004169 Modulators of dopamine neurotransmission
01/02/2003US20030004168 Mixture of hypotensive agent and calcium channel blockers; cardiovascular disorders
01/02/2003US20030004167 Imidazo-heterobicycles as factor Xa inhibitors
01/02/2003US20030004166 Novel triazine compounds useful as sorbitol dehydrogenase inhibitors
01/02/2003US20030004164 Anticancer agents; autoimmune diseases
01/02/2003US20030004163 Antiinflammatory agents; headaches; antiarthritic agents
01/02/2003US20030004162 Antidiabetic agents; dietetics
01/02/2003US20030004161 Anticancer agents; autoimmune diseases
01/02/2003US20030004160 Method for the preparation of oxazolidinones
01/02/2003US20030004159 Novel cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists
01/02/2003US20030004157 Neurokinin antagosnist receptor
01/02/2003US20030004156 Anticholesterol agents; cardiovascular disorders; antidiabetic agents; antiproliferative agents
01/02/2003US20030004155 Pharmaceutical compositions
01/02/2003US20030004154 New crystal forms of oxcarbazepine and processes for their preparation
01/02/2003US20030004153 Novel heteroaryl-diazabicycloalkanes
01/02/2003US20030004152 Method of treating sexual disturbances
01/02/2003US20030004151 Cyclic derivatives as modulators of chemokine receptor activity
01/02/2003US20030004149 Antiangiogenic compounds and an assay for inhibitors of cell invasion
01/02/2003US20030004148 Regulation of meiosis
01/02/2003US20030004147 5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia
01/02/2003US20030004146 Compositions for preventing hormone induced adverse effects
01/02/2003US20030004145 Endometriosis, memopause therapy; controlling dosage cycles
01/02/2003US20030004144 Anticancer agents; skin disorders
01/02/2003US20030004143 In situ supplying; anticancer, antitumor agents
01/02/2003US20030004142 In situ supplying; anticancer, antitumor agents
01/02/2003US20030004141 Prevention atherosclerosis; in situ supplying a metalloproteinase inhibitor
01/02/2003US20030004140 Methods for modulating cell-adhesion mediated drug resistance
01/02/2003US20030004139 Antidiabetic agents
01/02/2003US20030004138 Hypoglycemic agents; antidiabetic agents; dietetics
01/02/2003US20030004137 Muscle relaxants, controlling immunology, strokes, antidiabetic agents
01/02/2003US20030004136 IL-8 receptor ligands-drugs for inflammatory and autoimmune diseases
01/02/2003US20030004135 Composition and method for the treatment of dysglucaemia
01/02/2003US20030004132 Binding to galectins; therapy for autoimmune disease
01/02/2003US20030004131 Oenothein medicaments
01/02/2003US20030004130 Homogeneous pharmaceutical compositions containing zidovudine and lamivudine
01/02/2003US20030004129 Formulations of adenosine a1 agonists
01/02/2003US20030004128 Formulatios of adenosine a1 agonists
01/02/2003US20030004127 Formulations of adenosine a1 agonists
01/02/2003US20030004126 Formulations of adenosine A1 agonists
01/02/2003US20030004119 Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
01/02/2003US20030004118 Antibiotic/benzoyl peroxide dispenser
01/02/2003US20030004117 Methods for inhibiting angiogenesis
01/02/2003US20030004116 Noni extract for prevention of disease
01/02/2003US20030004115 Pharmaceutical preparation and method for treatment of diabetes
01/02/2003US20030004110 Therapeutic compositions and methods for enhancing angiogenesis
01/02/2003US20030004106 Interleukin-1 receptor antagonist-related molecules and uses thereof
01/02/2003US20030004104 Methods for increasing schwann cell survival
01/02/2003US20030004102 Genetic engineering; immunosuppressants, anticancer agents
01/02/2003US20030004100 Method of modifying the release profile of sustained release compositions
01/02/2003US20030004093 Method for identifying compounds for inhibition of neoplastic lesions
01/02/2003US20030004091 Medicinal combination useful for in vivo exogenic transfection and expression
01/02/2003US20030003559 Nucleotide sequences coding polypeptide for use in the treatment of diabetes, kidney, and liver disorders
01/02/2003US20030003520 FXR receptor-mediated modulation of cholesterol metabolism